Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 602 participants.

Also called NCT07630454

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 602 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07630454
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07630454. Randomized; single masking; primary purpose prevention. Start 2026-08-01 (anticipated); primary completion 2029-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
Acronym
TEAR-AF-HFpEF
Condition
Tirzepatide
Intervention (Drug)
Tirzepatide
Intervention (Behavioral)
Structured Lifestyle Intervention
Lead sponsor
Yunlong Wang (class: other)
Collaborator
Shanghai Zhongshan Hospital (class: other)

Record details

Record id
cardio:ct-nct07630454
Content hash
620b4704782f1fc902871ec3d161ddb0f1eb022e9bea7a49a7fedfb2462df738